Rhophylac ZLB Bioplasma AG, Switzerland - Treatment for Prevention of Rho(D) Sensitization

Rhophylac is a highly purified, plasma-derived product comprised of Rho(D) Immune Globulin (Human) for IV or IM administration. Rhophylac is primarily indicated for the prevention of hemolytic disease of the fetus and newborn (HDN), and also indicated to prevent Rho(D) sensitization after transfusion of Rh-positive blood type to Rh-negative patient.

Latest FDA Drug Approvals...

2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Oct | Dec

Daily MedNews
Pharma Industry News
New Drug Applications
New Drug Approvals
Clinical Trial Results
Generic Drug Approvals